Jiangxi Synergy Pharmaceutical (300636.SZ): The raw material drug of Telmisartan Potassium has been approved by the China Food and Drug Administration (CDE).
Tonghe Pharmaceutical Co., Ltd. (300636.SZ) announced that the company recently received approval from the National Medical Products Administration (NMPA) Drug Evaluation Center (CD...
Jiangxi Synergy Pharmaceutical (300636.SZ) announced that the company recently obtained the approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration. The company's submission for the raw material of "Valsartan Potassium" has been approved by the CDE. Valsartan Potassium is used for the treatment of primary hypertension in adults.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
